Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Christopher KennardEmeritus Professor of Clinical Neurology, Professor Christopher Kennard joins the Medical Sciences Division as its new interim Head of Division today, replacing Professor Alastair Buchan, who will be taking a new role as the University’s Head of Brexit Strategy. Professor Kennard knows the Division well, having served, until his retirement late last year, as the Head of the Nuffield Department of Clinical Neuroscience, one of the 16 departments within the Division. Prior to his arrival in Oxford, Prof Kennard was the Deputy Principal for the Faculty of Medicine at Imperial College, London.

Professor Christopher Kennard commented:  “It is a great honour to have been invited by the VC to take on the role of interim Head of the Medical Sciences Division, following Alastair Buchan’s move to become the Head of Brexit Strategy for the University. During his nine year tenure he successfully led the Division to its premier international position and made major contributions in many areas. I very much look forward to being able to contribute to the Division’s continuing success and to work with such an exceptionally talented group of teachers and researchers.”

Professor Louise Richardson, Vice-Chancellor, said: “I am deeply grateful to Professor Christopher Kennard for agreeing to assume the role of Head of Division on an interim basis until a new Head of Division is appointed. The Division sought Council’s approval for the process of selecting a new Head of Division, and we expect to have a new head in place before Professor Alastair Buchan’s term would ordinarily have concluded.”

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.